Novartis and Sawai end Japan ciclosporin case
This article was originally published in Scrip
Executive Summary
Novartisand the Japanese generics company Sawai have agreed to end litigation relating to the immunosuppressant ciclosporin. The Swiss firm instigated legal action against Sawai in the Tokyo district court in December 2006, claiming the company's generic ciclosporin capsules infringed patents for its original branded product Neoral. Without disclosing terms, Sawai said that the action had now been halted and that sales of its product would continue unaffected.